Psyence Biomedical Ltd.’s Debt to Equity at a glance
Psyence Biomedical Ltd. reports debt to equity of 0 for Mar 2025. The prior period recorded -0.95 (Mar 2024). Year over year the metric moved +0.95 (+100%). The rolling three-period average stands at -0.32. Data last refreshed Nov 20, 2025, 7:10 PM.
Latest reading
0 · Mar 2025
YoY movement
+0.95 (+100%)
Rolling average
-0.32
Current Debt to Equity
0
+0.95
+100%
Rolling average
-0.32
Latest Value
0
Mar 2025
YoY Change
+0.95
Absolute
YoY Change %
+100%
Rate of change
3-Period Avg
-0.32
Smoothed
Narrative signal
Psyence Biomedical Ltd.’s debt to equity stands at 0 for Mar 2025. Year-over-year, the metric shifted by +0.95, translating into a +100% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How debt to equity shapes Psyence Biomedical Ltd.'s story
As of Mar 2025, Psyence Biomedical Ltd. reports debt to equity of 0. Study leverage posture, capital structure discipline, and balance sheet risk across multi-year periods.
Interpreting leverage levels
A rising debt-to-equity ratio shows greater reliance on borrowing. Moderate leverage can enhance returns, but excessive leverage increases financial risk in downturns.
Benchmarking within an industry
Capital intensity differs by industry. Utilities and telecom often run higher leverage while software firms trend lower. Always compare against relevant peers.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Psyence Biomedical Ltd. (PBM) FAQs
Answers tailored to Psyence Biomedical Ltd.’s debt to equity profile using the latest Financial Modeling Prep data.
What is Psyence Biomedical Ltd.'s current debt to equity?
As of Mar 2025, Psyence Biomedical Ltd. reports debt to equity of 0. This reading reflects the latest filings and price data for PBM.
How is Psyence Biomedical Ltd.'s debt to equity trending year over year?
Year-over-year, the figure shifts by +0.95 (+100%). Pair this context with revenue growth and free cash flow signals to gauge momentum for PBM.
Why does debt to equity matter for Psyence Biomedical Ltd.?
The debt-to-equity ratio compares total liabilities with shareholders’ equity to illustrate leverage. For Psyence Biomedical Ltd., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Psyence Biomedical Ltd.'s debt to equity above its recent average?
Psyence Biomedical Ltd.'s rolling three-period average sits at -0.32. Comparing the latest reading of 0 to that baseline highlights whether momentum is building or fading for PBM.
How frequently is Psyence Biomedical Ltd.'s debt to equity refreshed?
Data for PBM was last refreshed on Nov 20, 2025, 7:10 PM and updates automatically every 24 hours, keeping your valuation inputs current.